天目药业: 杭州天目山药业股份有限公司第十二届董事会第十四次会议决议公告

Group 1 - The company held its 14th meeting of the 12th Board of Directors on August 26, 2025, with all 9 directors present, complying with relevant laws and regulations [1] - The Board approved the 2025 semi-annual report, confirming that it accurately reflects the company's financial status and operational results, adhering to legal and regulatory requirements [2][3] - The Board decided to cancel the Supervisory Board and amend the Articles of Association to enhance corporate governance, with the powers of the Supervisory Board being transferred to the Audit Committee [2][3] Group 2 - The company plans to hold the 2025 third extraordinary general meeting of shareholders on September 12, 2025, to review the approved matters [5]